Effect of Gubenfangxiao decoction on respiratory syncytial virus-induced asthma and expression of asthma susceptibility gene orosomucoid 1-like protein 3 in mice

OBJECTIVE： To investigate the effect of Gubenfangxiao decoction （GBFXD） on respiratory-syncytial-virus （RSV） -induced asthma and the expression of asthma susceptibility gene, orosomucoid 1-1ike protein 3 （ORMDL3） in mice. METHODS： Seventy-two female BALB/c mice were randomly assigned to normal, model, GBFXD high dose, GBFXD moderate dose, GBFXD low dose and montelukast groups. An asthma model was induced via intraperitoneal injection and aerosol inhalation of ovalbumin （OVA） and repeated intranasal instillation of RSV in all mice, except those in the normal group. All treatments were administered at the first onset of asthma （within 8 weeks of model establishment） and the mice were euthanized after 28 days of treatment. The levels of transforming growth factor-β （TGF-β） and interleukin-6 （IL-6） in bronchoalveolar lavage fluid （BALF） of the mice were measured and the expression of asthma sus- ceptibility gene ORMDL3 in lung tissue was deter- mined using real-time polymerase chain reaction （RT-PCR） and western blotting. RESULTS： Expression of ORMDL3 and levels of TGF-β and IL-6 were significantly higher in the mod- el group （P 〈 0.05, P 〈 0.01） compared with the normal mice. Levels of ORMDL3, TGF-β and IL-6 were significantly lower in all three GBFXD treated groups （P 〈 0.05） compared with the model group. However, the levels in the GBFXD treatment groups did not differ significantly from the montelukast group. CONCLUSION： GBFXD had a therapeutic effect in this experimental model. The functional mechanism of GBFXD may involve multiple factors, including alleviation of airway inflammation, down-regulation of asthma susceptibility gene ORMDL3 and inhibition of airway remodeling.

固本防哮饮对哮喘缓解期小鼠的治疗作用

目的观察固本防哮饮对哮喘缓解期小鼠的影响。方法通过腹腔注射和雾化吸入卵蛋白(OVA)制备哮喘缓解期小鼠模型。在停止激发后给药4周,末次给药后24h观察小鼠气道反应性、肺泡灌洗液(BALF)中炎性细胞总数和细胞分类、白细胞介素-4(IL-4)和γ-干扰素(IFN-γ)水平以及肺脏病理学变化。结果固本防哮饮可以降低模型小鼠的气道高反应性,降低BALF中炎性细胞总数及嗜酸性粒细胞和中性粒细胞比例,升高IFN-γ水平,减轻支气管周围炎性细胞浸润,减轻气道重塑。结论固本防哮饮降低气道高反应性、减轻支气管周围嗜酸性粒细胞浸润以及调节机体IFN-γ水平可能是其防止哮喘复发的作用机制。

固本防哮饮联合定喘敷贴膏治疗儿童哮喘缓解期疗效评价

目的:评价固本防哮饮联合定喘敷贴膏治疗儿童哮喘缓解期肺脾气虚证的疗效。方法:采用中心随机、平行分组对照,多中心临床研究,4个中心共263例哮喘缓解期患儿完成本次研究,其中试验组132例、对照组131例,试验组采用固本防哮饮口服联合定喘敷贴膏穴位敷贴;对照组用普米克都保(布地奈德)吸入,疗程均为12个月。结果:1)主要疗效指标评价:治疗6个月和12个月时,2组患儿哮喘发作次数、呼吸道感染次数均较治疗前有显著减少(P<0.01),其中12个月时呼吸道感染次数试验组显著低于对照组(P<0.05)。2)中医证候疗效指标评价:试验组和对照组对中医证候疗效指标均有明显改善效果,但试验组在改善鼻痒喷嚏、流涕、咳嗽、出汗、大便、舌象等症状和总症状积分方面要优于对照组(P<0.01,P<0.05)。2组证候总疗效比较,试验组总有效率为93.08%、对照组总有效率为82.31%,试验组明显优于对照组(P<0.05)。结论:固本防哮饮联合定喘敷贴膏治疗儿童哮喘缓解期安全有效。